CARB-X is backing a Center for Global Development (CGD) effort—NeoTest—to accelerate neonatal sepsis diagnostics toward market. The initiative is designed to reduce the gap between diagnostic prototypes and real-world uptake by combining milestone “push” funding with advanced market commitments (“pull” funding). CGD and CARB-X identified 43 firms developing neonatal sepsis tests that could potentially be adapted to newborn settings up to 59 days old, with target product profiles emphasizing point-of-care usability and the ability to rule in or out sepsis for initial care decisions. The planned 10-year, $60 million market-shaping facility includes $20 million in milestones, $10 million for implementation support, and $30 million for advanced uptake incentives. For the biotech sector, NeoTest is a concrete example of how diagnostics developers are being supported beyond bench validation—aiming to de-risk deployment timelines in low-resource settings.